A Phase 2 Study of Efatutazone, an Oral PPAR Agonist, In Combination With Paclitaxel in Patients With Advanced Anaplastic Thyroid Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 30 May 2019
Price : $35 *
At a glance
- Drugs Efatutazone (Primary) ; Paclitaxel
- Indications Thyroid cancer
- Focus Therapeutic Use
- 27 Nov 2018 Status changed from recruiting to active, no longer recruiting.
- 30 Jan 2018 Status changed from suspended to recruiting.
- 12 Jan 2018 Planned primary completion date changed from 1 Oct 2017 to 1 Jul 2019.